FDA CONTENT UNIFORMITY COMPLIANCE GUIDE: TESTING SPECS ARE REQUIRED for non-USP tablets and capsules that contain less than 50 mg of any active ingredient. In a recently issued "Compliance Policy Guide," FDA notes that current GMPs require "the establishment of scientifically sound and adequate specifications to assure" that products not subject to compendial requirements meet their purported standards. "Specifications for content uniformity are required, within this context," the guide states, "for tablets and capsules which contain less than 50 mg of any active ingredient." The requirements can be satisfied for such products, the guide adds, by adopting either USP test specifications, or "sound alternative specifications." The FDA guide also requires content uniformity specifications for relative standard deviation for both compendial and non-compendial products. The relative standard deviation specs are in addition to specifications for individual dosage unit assays. The guide points out that there has been "confusion" among tablet and capsule manufacturers as a result of a recent revision in the USP content uniformity requirements. Manufacturers must now include the relative standard deviation specification in order to limit large variations in test results. While "many firms have been reluctant to incorporate the relative standard deviation specification into their standard operating procedures," FDA notes, the USP monograph requirement must be met for a product to be considered in GMP compliance. FDA said that the requirement for specifications for both individual dosage unit assay and for relative standard deviation are applicable regardless of whether the product in question is subject to an NDA. The guide adds that "if an approved NDA does not currently provide for complete content uniformity testing, or provides specifications that are inconsistent with the USP monograph, the NDA holder must submit a change to provide for such testing."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.
